Post-GPI attachment to proteins 3
| Catalog# | Product Description | Host Species | Nature | Cross reactivity | Quantity | Volume | Price |
|---|---|---|---|---|---|---|---|
| CAB2-101AP | CAB2 antibodies N-terminal epitope | Rabbit | Affinity purified | h | 100.0 ug | 200 ul |
$245.00
|
| CAB2-112AP | CAB2 antibodies mid-region epitope | Rabbit | Affinity purified | h | 100.0 ug | 200 ul |
$245.00
|
| CAB2-121AP | CAB2 antibodies C-terminal epitope | Rabbit | Affinity purified | h | 100.0 ug | 200 ul |
$245.00
|
| CAB2-131AP | CAB2 antibodies C-terminal epitope | Rabbit | Affinity purified | h | 100.0 ug | 200 ul |
$245.00
|
| FITC-CAB2-101 | FITC-conjugated N-terminal CAB2 antibodies | Rabbit | FITC-conjugated antibodies | h | 100.0 ug | 200 ul |
$350.00
|
| FITC-CAB2-112 | FITC-conjugated mid-region CAB2 antibodies | Rabbit | FITC-conjugated antibodies | h | 100.0 ug | 200 ul |
$350.00
|
| FITC-CAB2-121 | FITC-conjugated C-terminal CAB2 antibodies | Rabbit | FITC-conjugated antibodies | h | 100.0 ug | 200 ul |
$350.00
|
| FITC-CAB2-131 | FITC-conjugated C-terminal CAB2 antibodies | Rabbit | FITC-conjugated antibodies | h | 100.0 ug | 200 ul |
$350.00
|
| P-CAB2-101 | N-terminal antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| P-CAB2-112 | Mid-region antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| P-CAB2-121 | C-terminal antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| P-CAB2-131 | Near C-terminal antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| PC-CAB2 | WB positive control for CAB2 | n/a | Protein in ready-to-use buffer | n/a | 0.0 ug | 150 ul |
$185.00
|
|
C
|
ertain loci on human chromosome 17q12 are frequently amplified in various types of cancers. One of such loci is PP1R1B-ERBB2-GRB7 which is greatly amplified in gastric and breast cancer. Search of other genes that reside close to this recombination hot spot or “fragile loci” led to discovery of several genes, one of these genes is a new theoretical protein MGC9753 is localized on chromosome 17 at cytogenetic location of 17q21.2. The detailed analyses of the amplicon structure in 330 breast tumors samples revealed a 280 kb common region of amplification that contains 10 genes that include 8 known genes. A highly significant association between amplification and expression levels was observed for 6 genes including ERBB2 and 2 uncharacterized hypothetical proteins, MGC9753 and MGC14832 in breast carcinoma and human gastric cancer samples (1, 2).
MGC9753 is located on human chromosome 17q12 and is in the amplicon cluster consist of PPP1R1B-STARD3-TCAP-PNMT-MGC9753-ERBB2-MGC14832-GRB7 with in the 120 kb region locus on human chromosome 17q12. The MGC9753 protein is a 7 transmembrane receptor with an extracellular six-cystein domain (3). The human and mouse MGC9753 protein is a 320 amino acid 7-transmembrane protein with 8 exxons exhibiting 90.6% total maino acid identity with human CAB2 aberrant protein, which lacked the 3rd transmembrane domain due to a frame shift mutation with in the ORF (3).
The CAB2 (MGC9753-selective) antibodies were generated in rabbits against synthetic N, mid-region and C-terminal peptides that are unique to MGC9753 protein. FabGennix Inc. has generated specific rabbit anti-MGC9753 polyclonal mono-epitope-specific antibodies utilizing linear or cyclic peptide methodology. These antibodies have been characterized for cross-reactivity with other members of the amplicon related proteins. FabGennix Inc. has produced antibodies to multiple epitopes of the same protein, to facilitate studies utilizing epitope analyses and other functional and interspecies assays. FabGennix Inc. also provides limited quantities of all antigenic blocking peptides for MGC9753 antibodies.
For research use only, not for diagnostic or therapeutic use.
Data Sheets
MSDS
General Information
Citations
Search FabGennix Product Citation Data Base
Search